NAV

Eritoran

Identification

Generic Name
Eritoran
DrugBank Accession Number
DB04933
Background

Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 1313.6562
Monoisotopic: 1312.843002884
Chemical Formula
C66H126N2O19P2
Synonyms
  • Eritoran
  • Eritorán
  • Éritoran
  • Eritoranum
External IDs
  • E5564
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Investigated for use/treatment in sepsis and septicemia.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Eritoran has been shown to down-regulate the intracellular generation of pro-inflammatory cytokines IL-6 and TNF-alpha in human monocytes.

Mechanism of action

Eritoran is a toll-like receptor 4 inhibitor.

TargetActionsOrganism
UToll-like receptor 4Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Approximately 55%, primarily to high-density lipoproteins.

Metabolism
Not Available
Route of elimination

Not Available

Half-life

50.4 to 62.7 hours

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Eritoran tetrasodiumFUO195TC7O185954-98-7FEMINZOAAWPBPP-RHMAUSBNSA-J

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Acylaminosugars
Alternative Parents
Hexose phosphates / Disaccharide phosphates / N-acyl-alpha-hexosamines / O-glycosyl compounds / Monoalkyl phosphates / N-acyl amines / 1,3-dicarbonyl compounds / Oxanes / Ketones / Secondary carboxylic acid amides
show 8 more
Substituents
1,3-dicarbonyl compound / Acetal / Acylaminosugar / Alcohol / Aliphatic heteromonocyclic compound / Alkyl phosphate / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Dialkyl ether
show 24 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
lipid As (CHEBI:68609)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
551541VI0Y
CAS number
185955-34-4
InChI Key
BPSMYQFMCXXNPC-MFCPCZTFSA-N
InChI
InChI=1S/C66H126N2O19P2/c1-7-11-15-19-22-25-26-27-28-29-30-32-34-38-42-46-57(70)67-60-64(82-49-47-54(80-6)45-41-36-18-14-10-4)62(86-88(73,74)75)56(51-79-5)85-65(60)83-52-55-61(72)63(81-48-43-39-35-24-21-17-13-9-3)59(66(84-55)87-89(76,77)78)68-58(71)50-53(69)44-40-37-33-31-23-20-16-12-8-2/h25-26,54-56,59-66,72H,7-24,27-52H2,1-6H3,(H,67,70)(H,68,71)(H2,73,74,75)(H2,76,77,78)/b26-25-/t54-,55-,56-,59-,60-,61-,62-,63-,64-,65-,66-/m1/s1
IUPAC Name
{[(2R,3R,4R,5S,6R)-4-(decyloxy)-5-hydroxy-6-({[(2R,3R,4R,5S,6R)-4-{[(3R)-3-methoxydecyl]oxy}-6-(methoxymethyl)-3-[(11Z)-octadec-11-enamido]-5-(phosphonooxy)oxan-2-yl]oxy}methyl)-3-(3-oxotetradecanamido)oxan-2-yl]oxy}phosphonic acid
SMILES
CCCCCCCCCCCC(=O)CC(=O)N[C@H]1[C@@H](OP(O)(O)=O)O[C@H](CO[C@@H]2O[C@H](COC)[C@@H](OP(O)(O)=O)[C@H](OCC[C@@H](CCCCCCC)OC)[C@H]2NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](O)[C@@H]1OCCCCCCCCCC

References

General References
  1. Rossignol DP, Wasan KM, Choo E, Yau E, Wong N, Rose J, Moran J, Lynn M: Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother. 2004 Sep;48(9):3233-40. [Article]
KEGG Drug
D04043
PubChem Compound
6912404
PubChem Substance
175426908
ChemSpider
5288721
BindingDB
50274760
ChEBI
68609
ChEMBL
CHEMBL501259
PDBe Ligand
E55
Wikipedia
Eritoran
PDB Entries
2z65 / 3ula

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentSevere Sepsis1
3RecruitingTreatmentCommunity-acquired Pneumonia, Influenza, COVID-19 / Coronavirus Disease 2019 (COVID‑19)1
2CompletedTreatmentInfection / Sepsis / Sepsis Syndromes / Septic Shock / Septicemia1
2CompletedTreatmentInsulin Sensitivity1
2TerminatedTreatmentInsulin Sensitivity1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00458 mg/mLALOGPS
logP6.98ALOGPS
logP15.5Chemaxon
logS-5.5ALOGPS
pKa (Strongest Acidic)0.55Chemaxon
pKa (Strongest Basic)-3.6Chemaxon
Physiological Charge-4Chemaxon
Hydrogen Acceptor Count17Chemaxon
Hydrogen Donor Count7Chemaxon
Polar Surface Area293.63 Å2Chemaxon
Rotatable Bond Count59Chemaxon
Refractivity346.56 m3·mol-1Chemaxon
Polarizability152.32 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.9874
Blood Brain Barrier-0.9401
Caco-2 permeable-0.6624
P-glycoprotein substrateSubstrate0.7565
P-glycoprotein inhibitor IInhibitor0.6447
P-glycoprotein inhibitor IIInhibitor0.565
Renal organic cation transporterNon-inhibitor0.9358
CYP450 2C9 substrateNon-substrate0.752
CYP450 2D6 substrateNon-substrate0.8462
CYP450 3A4 substrateSubstrate0.6583
CYP450 1A2 substrateNon-inhibitor0.8413
CYP450 2C9 inhibitorNon-inhibitor0.7925
CYP450 2D6 inhibitorNon-inhibitor0.8903
CYP450 2C19 inhibitorNon-inhibitor0.7586
CYP450 3A4 inhibitorInhibitor0.5831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9351
Ames testNon AMES toxic0.6815
CarcinogenicityNon-carcinogens0.9384
BiodegradationNot ready biodegradable0.7395
Rat acute toxicity2.7745 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8974
hERG inhibition (predictor II)Non-inhibitor0.6143
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-05ot-4391000000-97231ee4a47c39336dbb
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-03fr-2196000000-fe33ff613fbb49c22052
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9441000000-d4e48ee1c1130b276b13
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0cfr-9882001000-2ade420c3bf4bf5b9510
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9663030110-2c0fd132d80e954fc0ea
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-06di-9831000002-deab993a8e942499c05e
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-371.8752
predicted
DeepCCS 1.0 (2019)
[M+H]+373.9392
predicted
DeepCCS 1.0 (2019)
[M+Na]+381.33432
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Toll-like receptor 4
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Transmembrane signaling receptor activity
Specific Function
Cooperates with LY96 and CD14 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). Acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and ...
Gene Name
TLR4
Uniprot ID
O00206
Uniprot Name
Toll-like receptor 4
Molecular Weight
95679.19 Da
References
  1. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ, Lee JO: Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007 Sep 7;130(5):906-17. [Article]
  2. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, Agnew ML, Hampton CR, Rothnie CL, Spring DJ, Pohlman TH, Shimpo H, Verrier ED: Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation. 2006 Jul 4;114(1 Suppl):I270-4. [Article]

Drug created at October 21, 2007 22:23 / Updated at September 15, 2021 23:26